PDCD1 and cancer: Anti-PD-1 therapies such as pembrolizumab and nivolumab were first approved for melanoma (Wolchok et al., 2013) and have since shown exceptional results in other cancers as well (Tawbi et al., 2018; Doki et al., 2022).